MX2009012319A - Polipeptidos que se unen a receptores fc con funciones efectoras modificadas. - Google Patents

Polipeptidos que se unen a receptores fc con funciones efectoras modificadas.

Info

Publication number
MX2009012319A
MX2009012319A MX2009012319A MX2009012319A MX2009012319A MX 2009012319 A MX2009012319 A MX 2009012319A MX 2009012319 A MX2009012319 A MX 2009012319A MX 2009012319 A MX2009012319 A MX 2009012319A MX 2009012319 A MX2009012319 A MX 2009012319A
Authority
MX
Mexico
Prior art keywords
polypeptides
antibodies
region
cdr3 region
variant
Prior art date
Application number
MX2009012319A
Other languages
English (en)
Inventor
Olivier Leger
Greg Elson
Original Assignee
Novimmune Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novimmune Sa filed Critical Novimmune Sa
Publication of MX2009012319A publication Critical patent/MX2009012319A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Transplantation (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Se describen procesos para producir un polipéptido variante (por ejemplo, anticuerpos), que tienen características de unión modificadas para el receptor IIA de Fc gamma humano (CD32A), que conduce a una inhibición incrementada de los mediadores proinflamatorios, mientras que se mantiene la unión al antígeno objetivo vía su porción Fv, procesos los cuales comprenden alterar los polipéptidos mediante la susutitución de al menos dos residuos de aminoácido en la posición EU 325, 326 ó 328 de una región de CH2 de la IgG humana, para una secuencia selecionada de SAAF, SKAF, NAAF y NKAF. También se describen moléculas, particularmente polipéptidos, más particularmente inmunoglobulinas (por ejemplo, anticuerpos), que incluyen una región CDR3 variante, en donde la región CDR3 variante incluye al menos un aminoácido modificado con relación a una región CDR3 del tipo silvestre. Los polipéptidos que pueden generarse de acuerdo con los métodos de la invención son altamente variables, y pueden incluir anticuerpos y proteínas de fusión que contienen una región Fc o una porción biológicamente activa de la misma.
MX2009012319A 2007-05-14 2008-05-14 Polipeptidos que se unen a receptores fc con funciones efectoras modificadas. MX2009012319A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US93027607P 2007-05-14 2007-05-14
PCT/IB2008/003978 WO2009101479A2 (en) 2007-05-14 2008-05-14 Fc receptor-binding polypeptides with modified effector functions

Publications (1)

Publication Number Publication Date
MX2009012319A true MX2009012319A (es) 2010-03-01

Family

ID=40957323

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009012319A MX2009012319A (es) 2007-05-14 2008-05-14 Polipeptidos que se unen a receptores fc con funciones efectoras modificadas.

Country Status (14)

Country Link
US (3) US8546539B2 (es)
EP (1) EP2173381B1 (es)
JP (6) JP2010526868A (es)
CN (1) CN101720232B (es)
AU (1) AU2008350535B2 (es)
CA (1) CA2689680C (es)
DK (1) DK2173381T3 (es)
ES (1) ES2441189T3 (es)
IL (1) IL202107A (es)
MX (1) MX2009012319A (es)
PL (1) PL2173381T3 (es)
PT (1) PT2173381E (es)
SI (1) SI2173381T1 (es)
WO (1) WO2009101479A2 (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101720232B (zh) * 2007-05-14 2013-07-10 诺维莫尼公司 具有修饰的效应器功能的fc受体结合型多肽
IE20090514A1 (en) * 2009-07-06 2011-02-16 Opsona Therapeutics Ltd Humanised antibodies and uses therof
JP6289098B2 (ja) * 2011-01-10 2018-03-07 ノビミューン エスアー 抗ｔｌｒ４抗体およびその使用法
EP2831117B1 (en) * 2012-03-29 2017-11-01 NovImmune SA Anti-tlr4 antibodies and uses thereof
JP2016539925A (ja) 2013-10-22 2016-12-22 ノビミューン エスアー Ｔｌｒ４リガンドまたは他のバイオマーカーのレベルが上昇した患者における障害の診断および処置を行うための方法および組成物
EP3083684A1 (en) 2013-12-06 2016-10-26 NovImmune SA Anti-tlr4 antibodies and methods of use thereof
EP3332256A1 (en) * 2015-08-06 2018-06-13 NovImmune SA Methods and compositions for identifying patient populations for diagnosis and treatment of tlr4-dependent disorders
WO2018183520A1 (en) * 2017-03-28 2018-10-04 Lyvgen Biopharma Holdings Limited Therapeutic agents and methods for enhancing immune responses in tumor microenvironment
AU2018346264A1 (en) * 2017-10-03 2020-04-23 Merck Patent Gmbh Cysteine engineered antigen-binding molecules
AU2020268399A1 (en) * 2019-05-09 2021-10-28 Genentech, Inc. Methods of making antibodies
AU2021208630A1 (en) * 2020-01-17 2022-07-21 University Of Tennessee Research Foundation Chimeric antigen receptors for removal of amyloid
WO2021212222A1 (en) * 2020-04-20 2021-10-28 Edesa Biotech Research Inc. Compositions and methods for treatment of acute respiratory distress syndrome
US20240018228A1 (en) * 2020-08-28 2024-01-18 Board Of Regents, The University Of Texas System Antibodies specific to ccl21 and methods of use
WO2024040115A2 (en) * 2022-08-16 2024-02-22 University Of Vermont And State Agricultural College ANTIBODIES FOR PLATELET FCγRIIA AND RELATED METHODS OF USE
WO2024040195A1 (en) 2022-08-17 2024-02-22 Capstan Therapeutics, Inc. Conditioning for in vivo immune cell engineering

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US993904A (en) 1911-02-28 1911-05-30 Ribbon Metals Syndicate Ltd Apparatus for making metal strips, foil, sheets, or ribbons.
FR2413974A1 (fr) 1978-01-06 1979-08-03 David Bernard Sechoir pour feuilles imprimees par serigraphie
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
WO1988001513A1 (en) 1986-08-28 1988-03-10 Teijin Limited Cytocidal antibody complex and process for its preparation
DE69029036T2 (de) 1989-06-29 1997-05-22 Medarex Inc Bispezifische reagenzien für die aids-therapie
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
JPH06507398A (ja) 1991-05-14 1994-08-25 リプリジェン　コーポレーション Ｈｉｖ感染治療のための異種複合抗体
DE69329503T2 (de) 1992-11-13 2001-05-03 Idec Pharma Corp Therapeutische Verwendung von chimerischen und markierten Antikörpern, die gegen ein Differenzierung-Antigen gerichtet sind, dessen Expression auf menschliche B Lymphozyt beschränkt ist, für die Behandlung von B-Zell-Lymphoma
US5820858A (en) 1993-05-28 1998-10-13 The Scripps Research Institute Methods and compositions for inhibiting CD14 mediated cell activation
SI1068241T1 (sl) 1998-04-02 2007-12-31 Genentech Inc Protitelesne variante in njihovi fragmenti
WO1999051642A1 (en) 1998-04-02 1999-10-14 Genentech, Inc. Antibody variants and fragments thereof
US6528624B1 (en) 1998-04-02 2003-03-04 Genentech, Inc. Polypeptide variants
KR100887482B1 (ko) 1999-01-15 2009-03-10 제넨테크, 인크. 효과기 기능이 변화된 폴리펩티드 변이체
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
US20040132101A1 (en) * 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
AU2003217912A1 (en) * 2002-03-01 2003-09-16 Xencor Antibody optimization
US7662925B2 (en) * 2002-03-01 2010-02-16 Xencor, Inc. Optimized Fc variants and methods for their generation
US8188231B2 (en) 2002-09-27 2012-05-29 Xencor, Inc. Optimized FC variants
US8623353B1 (en) 2003-09-23 2014-01-07 Technische Universitat Munchen TLR2 antagonistic antibody and use thereof
DK1711531T3 (da) * 2003-12-10 2012-04-30 Novimmune Sa Neutraliserende anti-TLR4/-MD-2-antistoffer og fremgangsmåder til anvendelse deraf
US7674884B2 (en) 2003-12-10 2010-03-09 Novimmune S.A. Neutralizing antibodies and methods of use thereof
US7312320B2 (en) 2003-12-10 2007-12-25 Novimmune Sa Neutralizing antibodies and methods of use thereof
WO2006085967A2 (en) * 2004-07-09 2006-08-17 Xencor, Inc. OPTIMIZED ANTI-CD20 MONOCONAL ANTIBODIES HAVING Fc VARIANTS
US7632497B2 (en) * 2004-11-10 2009-12-15 Macrogenics, Inc. Engineering Fc Antibody regions to confer effector function
US8029794B2 (en) * 2004-12-10 2011-10-04 Novimmune S.A. Combining therapies targeting multiple toll-like receptors
EP1871808A2 (en) 2005-03-31 2008-01-02 Xencor, Inc. Fc VARIANTS WITH OPTIMIZED PROPERTIES
CN101720232B (zh) * 2007-05-14 2013-07-10 诺维莫尼公司 具有修饰的效应器功能的fc受体结合型多肽
JP6289098B2 (ja) * 2011-01-10 2018-03-07 ノビミューン エスアー 抗ｔｌｒ４抗体およびその使用法
EP2831117B1 (en) * 2012-03-29 2017-11-01 NovImmune SA Anti-tlr4 antibodies and uses thereof

Also Published As

Publication number Publication date
DK2173381T3 (da) 2013-12-02
PL2173381T3 (pl) 2014-03-31
WO2009101479A2 (en) 2009-08-20
AU2008350535B2 (en) 2013-08-22
PT2173381E (pt) 2013-12-13
US9688755B2 (en) 2017-06-27
CN101720232A (zh) 2010-06-02
EP2173381A2 (en) 2010-04-14
WO2009101479A3 (en) 2010-02-25
IL202107A0 (en) 2011-08-01
CA2689680A1 (en) 2009-08-20
IL202107A (en) 2014-05-28
JP2014005306A (ja) 2014-01-16
US8546539B2 (en) 2013-10-01
CN101720232B (zh) 2013-07-10
JP2018087234A (ja) 2018-06-07
SI2173381T1 (sl) 2014-01-31
CA2689680C (en) 2017-11-07
JP2010526868A (ja) 2010-08-05
JP6360128B2 (ja) 2018-07-18
ES2441189T3 (es) 2014-02-03
US20120142098A1 (en) 2012-06-07
US20140038287A1 (en) 2014-02-06
AU2008350535A1 (en) 2009-08-20
EP2173381B1 (en) 2013-10-02
US20170298129A1 (en) 2017-10-19
JP2017036333A (ja) 2017-02-16
JP2020111613A (ja) 2020-07-27
JP2015017133A (ja) 2015-01-29

Similar Documents

Publication Publication Date Title
MX2009012319A (es) Polipeptidos que se unen a receptores fc con funciones efectoras modificadas.
AU2016262662B2 (en) Antibodies that bind csf1r
RU2019121902A (ru) Поливалентные модуляторы регуляторных t-клеток
WO2005040217A3 (en) Antibodies having a mutated amino acid residue at position 268 (ch2 region) in constant regions
UA86605C2 (ru) Антитело, которое содержит вариант исходного человеческого fс-участка
JP2020508655A5 (es)
RU2022101604A (ru) Улучшенные отдельные вариабельные домены иммуноглобулина, связывающиеся с сывороточным альбумином
JP2017512063A5 (es)
JP2020520231A5 (es)
WO2006110292A3 (en) Temperature-triggered immobilization and purification of antibodies
JP2016508153A5 (es)
WO2007121354A3 (en) Binding proteins comprising immunoglobulin hinge and fc regions having altered fc effector functions
WO2016057769A3 (en) Glycoengineered antibody drug conjugates
SG196697A1 (en) Binding proteins, including antibodies, antibody derivatives and antibody fragments, that specifically bind cd154 and uses thereof
RU2016108703A (ru) Антитело, специфически связывающееся с glp-1r, и его слитый с glp-1 белок
NZ596865A (en) Single-chain multivalent binding proteins with effector function
WO2007048037A3 (en) METHODS FOR GENERATING MONOVALENT IgG
DK1709081T3 (da) Fusionspolypeptider, der kan aktivere receptorer
RU2013140350A (ru) Антитела против человеческого il33r и их применение
CA2502904A1 (en) Alteration of fcrn binding affinities or serum half-lives of antibodies by mutagenesis
WO2005056600B1 (en) Monoclonal antibodies that bind or neutralize dengue virus
HRP20230528T1 (hr) Bispecifične molekule t stanica aktivirane proteazom
CN112218892A (zh) 新型抗ctla-4抗体多肽
JP2017509335A5 (es)
NZ724904A (en) Hybrid immunoglobulin containing non-peptidyl linkage

Legal Events

Date Code Title Description
FG Grant or registration